Advagene Biopharma Co., Ltd. reported earnings results for the half year ended June 30, 2022. For the half year, the company reported net loss was TWD 55.98 million compared to TWD 39.84 million a year ago. Basic loss per share from continuing operations was TWD 1.13 compared to TWD 0.83 a year ago.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
22.2 TWD | +0.45% | -3.06% | -12.60% |
1st Jan change | Capi. | |
---|---|---|
-12.60% | 36.5M | |
+18.97% | 45.34B | |
+41.98% | 40.42B | |
-10.06% | 37.92B | |
+31.15% | 31.75B | |
-7.79% | 27.71B | |
+13.32% | 26.52B | |
+43.05% | 13.96B | |
+31.28% | 12.44B | |
-7.41% | 11.26B |
- Stock Market
- Equities
- 6709 Stock
- News Advagene Biopharma Co., Ltd.
- Advagene Biopharma Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022